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1. Introduction  
Pre-eclampsia (PE, also called gravidic toxemia) is a hypertensive disorder that affects 5% of 
all pregnancies. It occurs during the second half of pregnancy (Carty et al, 2010). Affected 
women experience high blood pressure, fluid retention, nausea, and headaches. If not 
treated, PE leads to convulsions (eclampsia), kidney failure, liver failure and death. 
Screening tests for PE are poorly predictive and the "gold standard marker" is still to be 
discovered in order to assist the clinician in the prognosis of the pathology. The underlying 
causes of the development of the pathology are often unknown and the late diagnosis of the 
disease results in premature delivery of the fetus, which is considered to be the most 
definitive method to minimize PE complications. PE is still a major problem in Obstetrics 
and Gynecology and is the cause of several maternal deaths. 
PE is a multifactorial disease whose pathogenesis is not solely vascular, genetic, 
immunologic, or environmental, but is a complex combination of factors (Ilekis et al., 2007). 
The heterogeneity of the disease is suggested by diverse clinical manifestations such as mild 
or severe PE, early onset (<34 weeks) or late onset (>34 weeks) of the disease and presence 
or absence of associated IUGR (intrauterine growth restriction) (Dekker, 1999). Also women 
with asthma, obesity, maternal infections, insulin resistance or adverse lipid metabolic 
profile have an increased incidence of PE. (Carty et al., 2010) Moreover, a population-based 
cohort study suggests that women with early-onset PE are at greater risk of cardiovascular 
disease later in life (Irgens, 2007). Although its aetiology remains unclear, there have been 
significant advances in the understanding of the pathophysiology of the disorder. The 
primary lesion is thought to be due to deficient trophoblast invasion of the maternal spiral 
arteries by the end of first trimester of pregnancy and the beginning of the second trimester, 
leading to underperfusion of the uteroplacental unit. It is well documented today that the 
cause of the development of PE is a shallow invasion of maternal decidua and spiral arteries 
by extravillous trophoblasts (EVTs) (Fisher, 2004, McMaster et al., 2004). Successful human 
placentation depends on adequate transformation of the uteroplacental vasculature by EVT 
following proliferation, migration, and invasion of these cells into the maternal decidua 
(Cross et al., 1994, Strickland & Richards, 1992), this process of vascular remodeling rises to 
a peak by the end of the first trimester and declines rapidly thereafter (Aplin, 1991). At 
around 10-12 weeks of gestation (wg), cytotrophoblasts (CT) that are present in anchoring 
villi generate multilayered columns of EVTs that colonize the interstitium of the maternal 
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decidua, the inner third of the myometrium and the uterine blood vessels. This invasion 
results in the formation of a low resistance vascular system that is essential for fetal growth 
(Charnock-Jones et al., 2004). This developmental period is characterized by an important 
physiological switch in oxygen tension during the opening of the intervillous space. Before 9 
wg, placental oxygen tension is low (~20 mm Hg) and after the first trimester, it increases to 
~55 mm Hg (Jauniaux et al., 2000). During pregnancy, the depth of invasion by EVT into the 
uterine wall is critical and finely controlled. Poor invasion causes a lack of remodeling of the 
spiral arterioles and leads to a sustained hypoxic environment over the first trimester of 
pregnancy. This abnormal condition potentially leads to pathological conditions such as PE, 
IUGR, spontaneous abortion and stillbirth (Carty et al., 2010, Myatt & Miodovnik, 1999, 
Redman & Sargent, 2005). For instance, a limited trophoblast invasion of maternal vessels 
has been correlated to both PE (Sibai et al., 2005) and fetal growth restriction, whereas an 
excessive trophoblast invasion is associated with invasive mole, placenta accreta and 
choriocarcinoma (Wells, 2007).  
In PE, several aspects have been reported to contribute to the poor remodeling of the spiral 
arteries, including defective EVT differentiation toward the invasive phenotype, increased 
apoptosis, an imbalanced control of migratory and invasive EVT functions (Huppertz & 
Peeters, 2005, Kingdom et al., 2000). However, despite many years of extensive research on 
the disorders that are associated with abnormal placentation, the mechanisms leading to a 
successful pregnancy are far from being fully understood. It is likely that a fine balance 
between the expression of pro- and anti-invasive factors might regulate the depth and rate 
of placental invasion. Various growth factors and cytokines, such as EGF, HGF, TGF-, 
amphiregulin, IGF-II, and IL-1stimulate trophoblast differentiation toward an invasive 
phenotype (Cartwright et al., 1999,Lysiak et al., 1993); by contrast, limited data exist 
regarding possible negative regulators of trophoblast differentiation. Graham and Lala, 
(Graham & Lala, 1991) first demonstrated that TGF- produced primarily by the decidua 
inhibits trophoblast invasion. Subsequent studies revealed that TGF-3 inhibits trophoblast 
invasion following an interaction with endoglin, a component of the TGF-receptor 
complex (Caniggia et al., 1997, Irving & Lala, 1995). Recently, improved understanding of 
the pathogenesis of PE has raised the possibility that blood levels of antiangiogenic proteins 
might eventually be used to predict this devastating condition. Investigations on the cause 
of PE development have also pointed out the potential importance of angiogenic factors and 
their receptors. For instance, low VEGF (vascular endothelial growth factor) levels or 
increased production of VEGF antagonists such as the soluble fms-like tyrosine kinase-1 
(sFlt-1, also referred to as sVEGFR-1) have been proposed as possible mediators of PE 
(Levine et al., 2004). A key discovery in the field was the understanding that PE major 
phenotypes, such as hypertension and proteinuria are due to an excess of sFlt-1 that is made 
by the placenta and acts by neutralizing the pro-angiogenic proteins (VEGF) and placental 
growth factor (PlGF). More recently, soluble endoglin, another circulating anti-angiogenic 
protein was found to synergize with sFlt-1 and to contribute to the pathogenesis of PE. 
Abnormalities in these circulating angiogenic proteins are not only present during clinical 
PE, but seem also to antedate clinical symptoms by several weeks. Altogether these findings 
suggest that sequential angiogenic factor changes could have predictive value in PE. 
Therefore, current research in this field aims to discover more specific markers of the 
disease.  
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Although VEGF is selectively acting on any type of endothelial cell including placental 
endothelial cells, it is ubiquitously expressed. The existence of organ-specific angiogenic 
and/or anti-angiogenic factors has been postulated for many years (Dellian et al., 1996, 
Stewart & Wiley, 1981), but only recently received confirmation when a new factor named 
endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was characterized 
and sequenced (LeCouter et al., 2001). This factor was found to be expressed in testis, adrenal 
gland, ovary and placenta (LeCouter et al., 2001), in addition, its angiogenic action appeared to 
be restricted to endothelial cells derived from endocrine tissues (LeCouter et al., 2001). In 
endothelial cells isolated from steroidogenic tissues, EG-VEGF was shown to promote 
proliferation, survival and chemotaxis (LeCouter et al., 2001). In vivo delivery of adenoviruses 
encoding EG-VEGF resulted in endocrine tissue-specific angiogenesis (LeCouter et al., 2003). 
EG-VEGF also called prokineticin 1 (PROK1) is a member of a class of proteins named 
prokineticins (PROK) family that also includes Bv8, a frog peptide purified from the skin 
secretion of the yellow-bellied toad Bombina variegata (LeCouter et al., 2001), also known as 
prokineticin-2 (PROK2). Human EG-VEGF and Bv8 share the same G protein-coupled 
receptors, termed PROKR1 and PROKR2 (Masuda et al., 2002).  
2. Prokineticins  
The Prokineticin family comprises EG-VEGF/PROK1 and Bv8/PROK2, which were 
identified in frog, fish, reptiles and mammals. The names PROK1 and PROK2 were assigned 
to these proteins by Li et al. (M. Li et al., 2001) to reflect their functions in inducing specific 
and potent contractions of the smooth muscle of the gastrointestinal tract. Subsequently, 
LeCouter et al. (LeCouter et al., 2001) described a growth factor which induced a strong and 
specific mitogenic response in endocrine gland-derived endothelial cells. The similar effects 
induced by this protein and by VEGF led it to be named, EG-VEGF. Although there are 
several similarities in the functions of VEGF and EG-VEGF, the two factors are structurally 
unrelated. EG-VEGF and Bv8 share 44% amino acid identity and share a common protein 
structure motif. They have a conserved N-terminal sequence (AVITGA), which is essential 
for the activity of these proteins. Mutations to this sequence, by insertion of a methionine 
preceding the Nterminal alanine, substitution of the N-terminal alanine with a methionine 
or deletion of the first two amino acids (Negri et al., 2005), produce PROK receptor (PROKR) 
antagonists. Another feature of the PROKs is the presence of ten conserved cysteines, which 
are predicted to form five disulfide bonds (Boisbouvier et al., 1998, M. Li et al., 2001). The 
PROKs are the cognate ligands for two closely related G-protein-coupled receptors (GPCRs), 
termed PROKR1 and PROKR2, which share 85% amino acid identity and exhibit the greatest 
differences in their N-terminal sequences (D.C. Lin et al., 2002, Masuda et al., 2002). Their 
sequences are almost identical in the transmembrane domains (Soga et al., 2002), suggesting 
that their activation mechanisms are identical and that small molecule analogues will not 
discriminate between the receptors, as is the case for EG-VEGF and Bv8. The affinity of these 
factors for their receptors is similar, with Bv8 showing a moderately higher affinity for both 
receptors. PROKRs have been reported to couple either to Gs, Gi  or to Gq proteins (D.C. Lin 
et al., 2002, Soga et al., 2002). In adrenal cortex capillary endothelial (ACE) cells, activation of 
the receptors has been shown to be inhibited by pertussis toxin, suggesting Gi coupling. By 
contrast, in transfected CHO cells activation of the receptors has been shown to induce 
calcium mobilization and phosphoinositide hydrolysis (D.C. Lin et al., 2002, Soga et al., 
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2002), suggesting Gq coupling. Signalling through these receptors is linked to phospholipase 
C activation and generation of diacylglycerol and inositol phosphate, with potential 
downstream activation of protein kinase C, extracellular-signal regulated kinases (ERK) 1 
and 2, Akt and nitric oxide synthase (Hoogerwerf, 2006,D.C. Lin et al., 2002,R. Lin et al., 
2002). 
3. Prokineticins in reproduction 
Prokineticins were originally identified as regulators of intestinal contraction but 
subsequently shown to affect vascular function, neuronal survival, nociception, immune 
responses, and gonadotropin releasing hormone systems (Battersby et al., 2004, Dorsch et 
al., 2005, LeCouter et al., 2003, Maldonado-Perez et al., 2007). Quickly after their discovery, 
the members of this family showed differential specificities of expression and preferential 
sites of actions. While Bv8/PROK2 was associated to the neuronal system, EG-VEGF was 
more associated to the reproductive tract. EG-VEGF has been well studied in the ovary, 
uterus, testis, prostate and placenta (Battersby et al., 2004, Brouillet et al., 2010, Dorsch et al., 
2005, Fraser et al., 2005,Hoffmann et al., 2007,2006, Hoffmann et al., 2009, LeCouter et al., 
2001, LeCouter et al., 2003, Maldonado-Perez et al., 2007, Pasquali et al., 2006).  
3.1 Prokineticin expression in human reproductive systems 
Since its discovery, EG-VEGF has been reported to be highly expressed in the reproductive 
system, and it is now believed to play important roles in diverse facets of reproduction 
processes. While our group has been interested in the study of EG-VEGF and its receptors in 
the placenta, other groups have studied this factor in endometrium, ovary, prostate, uterus 
and testis. 
In the testis, EG-VEGF is predominantly expressed in testosterone-producing Leydig cells, 
and its receptors are expressed in vascular endothelial cells (LeCouter et al., 2001). The exact 
role of each type of receptor remains however to be elucidated.  
In the normal ovary, EG-VEGF is expressed in a dynamic way in elements of the sex cord–
stroma lineage. Maturing secondary follicles maintain strong EG-VEGF expression. However, 
in the antral follicle, EG-VEGF is expressed at low levels in theca cells. In the corpus luteum, 
the mRNA expression of EG-VEGF increases as the corpus luteum matures. The actions of EG-
VEGF in the ovary are likely to be mediated by both PROKR1 and PROKR2.  
In the endometrium, EG-VEGF, PROKR1 and PROKR2 expression peak during the window 
of implantation, a period that corresponds to the maximum of receptivity, and there is no 
temporal variation in the expression of PROK2, PROKR1, or PROKR2 during the same 
period. EG-VEGF and its receptors were localized to multiple cellular compartments, 
including glandular epithelial, stromal, endothelial cells in the endometrium and 
endothelial and smooth muscle cells in the myometrium. The elevation in EG-VEGF 
expression in the secretory phase of the menstrual cycle indicated a potential regulation of 
EG-VEGF by progesterone (Fraser et al., 2005, Kisliouk et al., 2003). 
Further support for a role of PROKs in reproductive functions can be gleaned from PROKR2 
and PROK2 knockout mice, which show hypoplasia of the reproductive tract (Dode et al., 
2006, Martin et al.). This phenotype has been explained by the lack of GnRH neurons in the 
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hypothalamus of these animals. Interestingly, mutations in PROK2 and PROKR2 have been 
identified in patients with Kallmann syndrome, a pathology that is defined by the 
association of hypogonadotropic hypogonadism (HH) with olfactory abnormalities 
(anosmia or hyposmia). Recently, homozygous loss-of-function mutations of PROK2 were 
described in families with HH, suggesting an autosomal recessive inheritance disorder. 
Hence PROKs seem to be directly involved in a major pathology of the reproductive system 
that is due to failure in sexual maturation. However, it is possible that the loss of PROKs 
might also have a direct local impact on to the observed atrophy of these tissues.  
3.2 Prokineticins in human placenta and decidua 
In the placenta, the expression of EG-VEGF was briefly reported by the group of Ferrara in 
2001. However, insightful work on EG-VEGF throughout pregnancy came from our group with 
a focus on early pregnancy and from the group of Dr Jabbour with more focus on the decidual 
unit, at the term of human gestation (Catalano et al., 2010 , Maldonado-Perez et al., 2007). 
3.2.1 Prokineticins at term of the pregnancy 
The group of Jabbour (Cook et al., 2010,Evans et al., 2008, Maldonado-Perez et al., 2007) has 
reported the localization of EG-VEGF and that of its receptors in term placenta and decidua; 
studied its signaling pathways, and demonstrated the effect of EG-VEGF on the expression 
of two inflammatory and vascular mediators, the cyclooxygenase (COX)-2 and IL-8 in third-
trimester placentas. IL-8 is a potent neutrophil chemoattractant and angiogenic factor, 
promoting endothelial cell chemotaxis (Winkler, 2003), whereas COX-2 is the inducible 
isoform of the enzyme involved in the synthesis of prostaglandins from arachidonic acid. 
Their results showed that EG-VEGF and PROKR1 were highly expressed in term placenta 
and were immunolocalized to syncytiotrophoblasts, cytotrophoblasts, fetal endothelium, 
and macrophages. EG-VEGF induced a time-dependent increase in the expression of IL-8 
and COX-2. These data suggest that EG-VEGF may have a novel role as a mediator of the 
inflammatory response in the placenta at the time of parturition. 
3.2.2 Prokineticins in early pregnancy: focus on the placenta 
As mentioned above, among the prokineticin members, EG-VEGF appeared to be an 
important actor for reproductive functions with indications of its potential involvement in 
human pregnancy, and particularly in placentation processes. The next paragraphs will 
summarize our main findings in this field. 
3.2.2.1 Hypothesis 
EG-VEGF was shown to be specific of the reproductive system and to be highly expressed in 
the placenta. Since its levels of expression were up-regulated by hypoxia, a strong attribute 
of placentation processes; and since a predictive marker for the launch of PE is still to be 
discovered; we performed a series of investigations to determine whether EG-VEGF could 
be a such marker. 
3.2.2.2 Methods  
To investigate the role of EG-VEGF in normal and pathological pregnancies, we used both 
human and mouse material. This consisted of placental tissues and sera collected at different 
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gestational ages. First-trimester human placentas were obtained from elective terminations 
of pregnancies. Shortly after collection, tissues were snap-frozen in dry ice and stored at  
-80°C (for protein and mRNA extraction), fixed in paraformaldehyde at room temperature 
(for immunohistochemistry), or used for in vitro primary culture. Collection and processing 
of human placentas was approved by the University Hospital Ethics Committee, and 
informed consent was obtained from each patient (Brouillet et al., 2010, Hoffmann et al., 
2007, 2006, Hoffmann et al., 2009). Mouse placentas were also collected at different 
gestational ages. Animal surgery was conducted following both institutional and European 
Community guidelines for the use of experimental animals. 
To test our hypotheses, different methods were used. The main ones will be emphasized in 
each paragraph. 
4. Main results 
4.1 Expression of prokineticins in human and mouse placenta 
Our first study on prokineticins in the placenta has reported the pattern of expression of EG-
VEGF and its analog, Bv8 (PROK2). This set of experiment has been performed using 
immunohistochemistry and western blot analysis. Whereas no expression of Bv8 was 
observed in the placenta, EG-VEGF was highly present in this tissue during the first 
trimester of pregnancy, with a strong expression in the syncytiotrophoblast. A comparison 
of EG-VEGF localization to that of VEGF showed that these factors are not localized to the 
same cell types, but rather show complementary localizations (Figure 1).  
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Fig. 1. Comparison of VEGF and EG-VEGF Immunoreactivity (Ir) in placental villous 
tissues. A, B show representative VEGF Ir, (brown color) at 6 and 8 weeks of gestation (wg), 
respectively. C, D show EG-VEGF Ir (brown color) at the same wg. Note that VEGF staining 
is present from 6 wg and EG-VEGF staining is only present at 8 wg. EG-VEGF and VEGF 
exhibit complementary sites of Ir in chorionic villi and EVT. Cytotrophoblast (Ct), Hobfauer 
cells (Ho), Extravillous trophoblast (EVT), syncytiotrophoblast (St). Scale bar = 20 m 
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EG-VEGF receptors were found in trophoblast cells, endothelial cells and EVT, suggesting 
potential roles of this factor in the control of placental development (Hoffmann et al., 2007, 
2006). Using quantitative RT-PCR we determined the pattern of expression of EG-VEGF and 
its receptors during the first trimester of human pregnancy. PROKR1 expression exhibited 
the same profile of expression as EG-VEGF, and PROKR2 was stably expressed during the 
first trimester with a slight increase by the end of this period (Figure.2). 
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Fig. 2. EG-VEGF (A), VEGF (B), PROKR1 (C) and PROKR2 (D) mRNA expression during 
the first trimester of pregnancy. Values overwritten with different letters are significantly 
different from each other (P < 0.05). 
The same results were found in mouse placenta during the first 10.5 days post coitum (dpc), 
corresponding to the first trimester of human pregnancy (Figure.3). We showed that EG-
VEGF and VEGF exhibit different patterns of expression and different localizations in the 
mouse placenta. EG-VEGF was mainly localized in the labyrinth whereas VEGF was present 
in glycogen and giant cells. EG-VEGF mRNA and protein levels were the highest before 10.5 
dpc whereas those of VEGF showed stable expression throughout gestation. PROKR1 
protein was localized to the labyrinth layer and showed the same pattern of expression as 
EG-VEGF, whereas PROKR2 expression was maintained over 10.5 dpc with both 
trophoblastic and endothelial cell localizations. Altogether these findings suggest that EG-
VEGF may have a direct effect on both endothelial and trophoblast cells and is likely to play 
an important role in placentation (Hoffmann et al., 2007, 2006). 
4.2 Role of EG-VEGF in the trophoblast invasion 
In the light of the data obtained in our first publications on the expression of this factor and its 
receptors, we decided to investigate the potential role of EG-VEGF in the control of trophoblast 
invasion into the maternal decidua, a requisite process for successful pregnancy. Human 
placental explants and EVT were used to determine EG-VEGF effect on migration, invasion 
and tube-like organization of EVT. We used the HTR-8/SVneo cells as a model for EVT cells 
(Graham et al., 1993). A wound healing assay was performed to examine the effect of EG-
VEGF on HTR motility. Cells were seeded in equal number into six-well plates. At confluence, 
cells were scratched and allowed to heal for 24 h. Our results showed that EG-VEGF is a potent 
inhibitor of EVT and migration. Measurement of EVT tube-like formation was performed 
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Fig. 3. Immunolocalizations of VEGF and EG-VEGF in mouse placenta. at 9.5, 14.5 and 
17.5 dpc. Labyrinth (L), Glycogen cells (GC), Giant cells (Gi), spongiotrophoblast (Sp). Scale 
bar = 50 m 
using time lapse microscopy. Our results showed that EG-VEGF inhibited the tube-like 
organization of EVT cells. The control of EVT invasion by EG-VEGF was confirmed in a set 
of experiments that employed placental explants. Villous explant cultures were established 
from first trimester human placentas (10–12 wg) as described previously (Caniggia et al., 
1999, Genbacev et al., 1993). It was particularly relevant to study EG-VEGF effects on 
trophoblast differentiation towards an invasive phenotype in a system in which the 
placental villous tissue architecture is maintained. Placental villous explants in culture 
preserve the topology of intact villi and closely mimic the formation of anchoring villi 
occurring in vivo by the end of first trimester of pregnancy (Caniggia et al., 1999, Genbacev 
et al., 1993). Figure. 4 shows representative photographs of placental villous tips at day 3 of 
culture in the absence or presence of EG-VEGF (50 ng/ml). In the control condition there 
was an obvious outgrowth of EVT from the distal end of the villous tip and migration into 
Matrigel. In contrast, in the presence of EG-VEGF, there was almost no outgrowth or 
migration of EVT into Matrigel. In additional experiments we demonstrated that these 
effects were mediated by the type 2 receptor of EG-VEGF, PROKR2 and involved MMP2 
and 9 activities, (Hoffmann et al., 2009). 
4.3 Role of EG-VEGF in placental angiogenesis.  
Pro-angiogenic effects of EG-VEGF were reported in many reproductive systems, 
confirming its direct involvement in angiogenesis. Using appropriate angiogenesis assays  
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Fig. 4. Effect of EG-VEGF on the invasion of EVT. Villous explants from 10 to 12 wg were 
maintained in culture for 6 days. EG-VEGF (50 ng/ml) treatment started 24 h after the 
launch of the culture and was assessed for 24h. Control experiments were run in parallel 
using explants from the same placenta. 
(Proliferation, migration, pseudo-vascular organization, spheroid sprouting) and functional 
studies (microvascular permeability and paracellular transport) we were able to answer an 
important biological question related to the role of EG-VEGF in placental development. EG-
VEGF effects were analyzed in placental microvascular endothelial cells “HPEC” and in 
macrovascular umbilical vein endothelial cells “HUVEC”. First, we showed that HPEC and 
HUVEC express both types of receptors, with a much higher level of expression in HPEC, 
(Brouillet et al., 2010). Furthermore, we showed that EG-VEGF increased HPEC but not 
HUVEC proliferation and migration (Brouillet et al., 2010). 
To determine EG-VEGF effect on the sprout formation, a three-dimensional in vitro angiogenesis 
system was used. Whereas no effect of EG-VEGF was observed on HUVEC sprouting, this 
factor increases HPEC sprouting. Figure. 5 shows representative photographs of HPEC 
spheroids at the time of their incubation and 12h later. To control the response of the cells, 
we examined the effect of the potent angiogenic factors, FGF-2. As expected, FGF-2 induced 
significant sprouting of the spheroids as compared to the control conditions. EG-VEGF 
induced the same level of sprouting in HPEC spheroids compared to that obtained with 
FGF2. 
0h
Contrôle
EG-VEGF 
(25 ng/mL) 
FGF-2 
(25 ng/mL) 
12h
 
Fig. 5. EG-VEGF, effect on the sprouting of HPEC spheroids. Representative photographs 
of spheroids formed from HPEC cells and cultured in collagen gel for 0 or 12h in the absence 
or presence of EG-VEGF (25ng/ml), FGF-2 (25 ng/ml).  
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In the placenta, the microvascular endothelium is known to participate in angiogenesis, 
maintenance of blood fluidity and is also a discriminating barrier in materno-fetal transports 
of solutes and nutrients (Murray, 2003, Rodgers, 1988), therefore a maintenance of a semi-
permeable barrier by the endothelium is critically important in endothelial cell function. 
Both permeability and paracellular transport of HPEC monolayers were assessed. HPEC 
permeability was measured in response to EG-VEGF and thrombin, an enhancer of 
electrolyte transport. The endothelial barrier was evaluated by trans-endothelial electrical 
resistance (TEER). Figure. 6A shows the percentage of increase in permeability of a 
monolayer of HPEC in response to thrombin (70 U/ml), EG-VEGF (25 ng/ml), or VEGF (25 
ng/ml). TEER was recorded every 5 min for 35 min. As expected, thrombin significantly 
increased HPEC permeability. Under EG-VEGF treatment, HPEC permeability increased as 
early as 5 min after treatment and was maintained for up to 20 minutes. The effect of EG-
VEGF on the paracellular transport was measured using [3H]-mannitol. The data 
summarizing the permeability coefficients for [3H]-mannitol transport in response to 
thrombin and EG-VEGF are presented in Figure. 6B. The basal permeability Coefficient 
(Papp) in HPEC was 1.7 x10-5cm/s. Thrombin almost doubled [3H]-mannitol transport 
through HPEC, and EG-VEGF increased this transport to almost the same levels achieved by  
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Fig. 6. Effects of EG-VEGF, VEGF and thrombin on the trans-endothelial electrical 
resistance (TEER) across HPEC monolayers. A Represents the decrease in the TEER of 
HPEC cells following their incubation with EG-VEG, VEGF or thrombin. The results were 
normalized to the respective controls. (B). Effects of EG-VEGF and thrombin on the 
paracellular transport of [3H]-mannitol in HPEC cells. (C) Represents the permeability 
coefficient of EG-VEGF and thrombin.  
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thrombin, Figure. 6C. More importantly, using siRNA and antibody blocking techniques, we 
demonstrated that PROKR1 mediates EG-VEGF angiogenic effects, whereas PROKR2 is 
rather involved in its effects on cellular permeability (Brouillet et al, 2010). Altogether, our 
results showed, for the first time, that EG-VEGF is a potent new angiogenic and survival 
factor for microvascular endothelial cells, and characterized the EG-VEGF mediated 
angiogenic processes. These finding propose a novel view of the regulation of angiogenesis 
normal placentation, (Brouillet et al, 2010). 
4.4 EG-VEGF regulation in human placenta 
4.4.1 Regulation by oxygen tension 
Low oxygen tension is a key parameter that controls gene expression during the first 
trimester of pregnancy. Moreover, the highest level of expression level of EG-VEGF and its 
receptor PROKR1 is observed during the hypoxic period of human placentation (Hoffmann 
et al., 2007, 2006). This observation prompted us to hypothesize that EG-VEGF and PROKR1 
mRNA might be regulated by oxygen tension in human trophoblast cells. To test this 
hypothesis, we incubated trophoblast cells isolated from first trimester placentas under 
either 20% O2 or 3% O2 and measured EG-VEGF and PROKR1 mRNA abundance using 
quantitative RT-PCR. As shown in Figure. 7A, a significant increase in both EG-VEGF (160% 
of normoxic control) and PROKR1 (200% of normoxic control) mRNA levels was observed 
under hypoxic conditions (3% O2). We then examined the effects of transcription and 
translation inhibitors on the hypoxic regulation of EG-VEGF expression. In the presence of 
the RNA polymerase inhibitor DRB, the hypoxic induction of EG-VEGF was completely 
abolished, whereas it was preserved in the presence of cycloheximide, a potent inhibitor of 
translation, Figure. 7B. These data suggest that hypoxia regulates EG-VEGF gene expression 
at the transcriptional level.  
EG-VEGF levels appeared to greatly vary during early pregnancy, progressively increasing 
until the 10th wg and rapidly dropping afterward. These dramatic changes appear to be 
correlated with the hypoxic developmental period of the placenta. This correlation is 
supported by the transcriptionally controlled up-regulation of EG-VEGF mRNA and 
concomitant increase of its protein levels that were observed in primary cultures of 
trophoblasts after 24 h of culture under reduced oxygen tension. This regulation was not 
unexpected as a functional hypoxia-response element (TACGTGCGGC) able to bind the 
hypoxia-inducible factor-1 has been identified in the human EG-VEGF promoter (LeCouter 
et al., 2001). Regulation of placental growth factors expression by oxygen tension is well 
established and has been described for several angiogenic factors, including VEGF, TGF3 
(Schaffer et al., 2003), and the soluble form of VEGF receptor-1 (s-flt) (H. Li et al., 2005, 
Nagamatsu et al., 2004). We also observed up-regulation of PROKR1 receptor expression 
under hypoxic conditions. A GenBank screen of the human PROKR1 promoter revealed the 
presence of one putative HIF-1 binding site, suggesting that the oxygen effect on PROKR1 
expression might occur through a pathway that involves HIF-1. However, we cannot 
totally exclude that other factors presenting peaks in their expression during the first 
trimester of pregnancy may also participate in the regulation of EG-VEGF expression. 
Human chorionic gonadotropin (hCG) and progesterone are two such candidates because 
they have been recently shown to stimulate EG-VEGF mRNA expression in human 
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luteinized granulosa cells (Fraser et al., 2005) and human endometrial tissue (Battersby et al., 
2004), respectively. 
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Fig. 7. Effect of hypoxia on EG-VEGF and PROKR1 mRNA expression in human 
trophoblast cells. Cytrophoblasts were isolated from 10 different placentas collected at 7-10 
weeks of gestation and cultured under either normoxic or hypoxic conditions. Panel A 
shows the RT-PCR amplification products for EG-VEGF and PROKR1 under either 20% or 
3% O2. B. shows the effect of DRB and CHX on basal and hypoxia-induced EG-VEGF 
mRNA expression in trophoblast cells. 
4.4.2 Regulation by human chorionic gonadotropin (hCG) 
During placental development, the hypoxic environment occurs from the beginning of 
implantation to the end of the first trimester. However, the strongest expression of EG-
VEGF is between the 8th and 11th wg, suggesting that other factors than hypoxia might 
regulate the EG-VEGF/ PROKR1/PROKR2 system. To date, little is known about the 
regulation of EG-VEGF and its receptors, and there is no enlightenment for the peak of 
expression of EG-VEGF by the end of the first trimester of pregnancy. During the first 
trimester of pregnancy, one dominant hormone, hCG exhibits the same pattern of 
expression as of EG-VEGF and displays similar effects on placental development (Licht et 
al., 2001, Malassine & Cronier, 2002). One of the earliest endocrine roles of hCG is to 
stimulate the corpus luteum to produce enough progesterone in order to establish 
pregnancy at the outset. In the placenta, hCG is well known to facilitate trophoblastic 
differentiation (Licht et al., 2001, Malassine & Cronier, 2002), and was reported to induce the 
expression of specific genes such as VEGF, leukemia inhibitory factor, and MMP-9, all 
central to the establishment of the feto-maternal interface (Licht et al., 2007, Zygmunt et al., 
2002). In human placenta, hCG is primarily produced by the syncytiotrophoblast and to a 
certain extent by the cytotrophoblast (Kirkegaard et al., 2011, Krantz et al., 2004, Rao & 
Lei, 2007, Shi et al., 1993). In normal pregnancies, detectable levels of hCG begin to appear 
in the maternal circulation about 2–3 weeks after conception and the peak is observed at 
~8–9 wg before declining significantly in the later stages of pregnancy. High serum hCG 
levels at mid-late pregnancy have been associated with PE, IUGR and Down's syndrome 
(DS).  
We investigated the regulation of EG-VEGF expression, and its receptors by hCG. Both 
placental explants (PEX) and primary cultures of trophoblast from the first trimester of 
www.intechopen.com
 Role of EG-VEGF in Human Placentation: Physiological and Pathological Implications 
 
299 
pregnancy were used to investigate this hypothesis. Our results show that i) LH/CGR, the 
hCG receptor, is expressed both in cyto- and syncytiotrophoblasts ii) hCG increases EG-
VEGF, PROKR1 and PROKR2 mRNA and protein expression in a dose and time-dependent 
manners iii) hCG increases the release of EG-VEGF from PEX conditioned media iv) hCG 
effects are transcriptional and post- transcriptional and v) the hCG effects are mediated by 
cAMP via cAMP response elements present in the EG-VEGF promoter region. Altogether, 
these results demonstrate a new role for hCG in the regulation of an emerging regulatory 
system of trophoblast invasion, EG-VEGF and its receptors (Figure 8).  
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Fig. 8. hCG effect on EG-VEGF expression and secretion. A shows a representative 
analysis of hCG (10, 50 and 100 IU/ml) effect on EG-VEGF mRNA expression in 
syncytiotrophoblast cells. B shows a temporal (0 to 48 h) and a dose dependence analysis of 
hCG effect on EG-VEGF secretion in placental conditioned media. C shows a time course 
(0h- 48h) effect of Forskolin on EG-VEGF secretion.  
5. EG-VEGF and pregnancy pathologies  
5.1 Prematurity  
Compelling recent findings suggest that PROKs and their receptors might play a crucial role 
in premature onset of labor. The labor onset is known to be associated with inflammatory 
cascades in the uteroplacental unit, and EG-VEGF has been shown to regulate the 
production of proinflammatory cytokines and to be involved in the inflammatory response 
in the placenta (Catalano et al., 2010 , Denison et al., 2008, Evans et al., 2008). Therefore, 
antagonism of prokineticin action may provide a therapy for preterm labor caused by early 
inflammation and contractile pathways. Further investigations are however required to 
demonstrate a direct involvement of EG-VEGF in the mechanisms of term and preterm 
labor. A particular interest should be given to EG-VEGF potential actions on the expression 
of factors that trigger parturition, particularly in the fetal membranes, major sites of 
prostaglandins synthesis and metabolism.  
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5.2 Preeclampsia and IUGR. 
5.2.1 EG-VEGF and Preeclampsia  
Since the discovery of EG-VEGF, our group has been interested in its study in PE. In fact, the 
combination of our previous data showing that EG-VEGF was abundantly expressed in 
human placenta during the first trimester of pregnancy; that its expression was up regulated 
by hypoxia; and that EG-VEGF regulates EVT invasion, suggested to us that EG-VEGF 
circulating levels might be altered in PE. We were first to report EG-VEGF circulating levels 
throughout human pregnancy and to show that they were significantly higher during the 
third trimester of pregnancy in PE patients compared to controls (Figure 9). These data raise 
the possibility that inappropriate expression or function of EG-VEGF or that of its receptors 
might contribute to major complications of pregnancy, such as PE, which is associated with 
abnormal trophoblast invasion and placental development. We now know that the origin of 
PE takes place during the first trimester of pregnancy and that any changes in protein 
expression after the establishment of the disease are considered to be consequences of the 
disease rather than causes of its development. Our data show that EG-VEGF expression is at 
its lowest levels by the end of the first trimester, suggesting that its greatest role should 
occur within that trimester. Moreover, given the correlation between the pattern of EG-
VEGF and PROKR1 expression with the hypoxic period of placental development and 
knowing that failure in placental angiogenesis is thought to contribute to PE development, 
one can speculate on the potential implication of this factor and/or its receptors in the 
development of PE. However, only a prospective study examining the expression of EG-
VEGF and/or PROKR1 during the first trimester of pregnancy in women who go on to 
develop PE will allow to provide an answer to this question. Clinical studies are ongoing to 
examine these hypotheses. Future studies are also required to determine the biological 
activities triggered by EG-VEGF in the human placenta and identify whether dysregulation 
of EG-VEGF expression may result in placental pathologies. 
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Fig. 9. EG-VEGF serum levels in non-pregnant and in pregnant women at the first, second 
and third trimesters. (graph on the left) and in PE women at second and third trimesters. 
Box plot demonstrates 10th, 25th, 50th, 75th, and 90th percentiles. (* P < 0.05, by ANOVA 
followed by Dunn’s Method).  
5.2.2 EG-VEGF and IUGR 
Nowadays, our group has been interested in the study of the direct effects of EG-VEGF on 
placental development and particularly on its direct actions on the villi growth and survival, 
under stressful conditions. These studies were performed in the perspective to investigate 
the role of EG-VEGF in the second most important pathology of human pregnancy, IUGR. 
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Hence, we investigated EG-VEGF effects on i) trophoblast proliferation, both in primary 
cytotrophoblast (CT) and in placental explants culture, and on trophoblast survival, ii) 
cytotrophoblast syncytialisation (measurement of syncytin 1 and 2 and β-hCG mRNA 
expression). To further investigate the role of EG-VEGF and its receptors in placental 
development, we determined their levels of expression, both at the mRNA and protein 
levels, in normal and IUGR placentas. We also determined the circulating levels of EG-
VEGF in sera collected from normal and IUGR pregnant women. Our results show that EG-
VEGF i) increased CT proliferation; both in primary and explant cultures ii) did not affect 
syncytin 1, syncytin 2 and β-hCG mRNA expression iii) EG-VEGF, PROKR1 and PROKR2 
mRNA and proteins levels are significantly increased in IUGR placentas, and iv) EG-VEGF 
circulating levels are significantly higher in IUGR patients. Altogether, these results identify 
a new placental growth factor during the first trimester of pregnancy, and provide evidence 
for its dysregulation in IUGR placentas. Changes in EG-VEGF, PROKR1 and PROKR2 in 
IUGR placentas, may well occur as a compensatory mechanism for this pathological 
condition. Further clinical investigations are required to demonstrate whether 
dysregulations in EG-VEGF and receptors in IUGR pregnancies are causes or consequences 
of the occurrence of this pathology. 
6. Future directions for research on EG-VEGF in human placentation 
6.1 EG-VEGF and implantation 
It has been demonstrated that EG-VEGF, but not PROK2, expression peaks during the 
midluteal  window of implantation, with immunolocalization to endometrial glandular 
epithelium, stromal and endothelial cells, and myometrial vascular endothelium as well as 
smooth muscle (Evans et al., 2009,Ngan et al., 2006,Salker et al.). In addition, it has been 
suggested that EG-VEGF could have a role in mediating the dysregulated vascular 
permeability that occur in ovarian hyperstimulation syndrome. The expression of PROKs 
and their receptors has also been reported in the fallopian tube from women with ectopic 
pregnancy (Tiberi et al.,2010). A dysregulation of these factors and their receptors has been 
demonstrated, suggesting a potential role for PROKs in fallopian tube function (Shaw et 
al.,2010). It has been postulated that these dysregulations could affect smooth muscle 
contractility in fallopian tube and embryo-tubal transport, providing a potential cause for 
ectopic pregnancy. More studies are required to evaluate whether PROKs are involved in 
these processes. 
We have shown that EG-VEGF acts as a permeability factor during the first trimester of 
pregnancy, one can therefore speculate that EG-VEGF might also act on the endometrium to 
facilitate implantation by increasing endothelial leakage at the implantation site, one of the 
earliest signs of implantation. More studies are also required to evaluate whether PROKs are 
involved in perimplantation, spiral arteriole formation and recruitment of immune cells, 
including uterine natural killer cells, which have been shown to increase in number during the 
implantation window and in early pregnancy (King et al., 1996a, King et al., 1996b). 
6.2 EG-VEGF and preeclampsia 
Although there is abundant evidence for the role of circulating anti-angiogenic factors as 
mediators of the clinical signs and symptoms of PE (Ahmed et al., 2000), there are no 
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definitive data linking early abnormalities in angiogenic factors with the impaired 
placentation in PE. Nowadays, our team is conducting a clinical study that aims to answer 
this question for EG-VEGF. This work relies on using blood samples collected from 500 
pregnant women during early pregnancy with a follow up of their pregnancies outcome. A 
positive correlation between high EG-VEGF levels and PE occurrence will suggest that this 
factor is directly involved in alterations that lead to PE development. Moreover, it will 
suggest that sequential measurement of anti-angiogenic factors may be useful as a screening 
test for premature PE, possibly when combined with other early predictive tests such as 
Doppler ultrasound (Grill et al., 2009). This will be important for timely referral of patients 
at high risk of developing early PE and for indicating the need for therapeutic measures 
when they become available. Large prospective studies with longitudinal specimen 
collection from early pregnancy are required to definitely assess whether sequential changes 
in angiogenic proteins can be used to predict preterm PE. 
7. Conclusion 
During the last six years, we were able to assemble interesting data in regards to the 
expression, role and regulation of EG-VEGF in normal and pathological human pregnancies. 
The combination between our fundamental research and clinical approaches allowed us to 
strongly propose EG-VEGF as a potential marker for PE. Our ongoing clinical study will 
allow us to undeniably determine the role of this factor in normal placentation and to 
conclude on its potential relevance as a marker of PE. Furthermore we plan to develop an 
animal model to test whether dysregulations in EG-VEGF levels are a cause or consequence 
of the development of this pathology.  
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